Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment (XenCART)

17 november 2026 uppdaterad av: Cellogen Therapeutics Pvt. Ltd.

Phase I Clinical Trial of CD20/19 Chimeric Antigen Receptor CAR T Cells in Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia or Lymphoma

XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 dose escalation design with DSMB review after each cohort will evaluate sequential dose levels of 1 2 and 4 x 10 to the power 6 CAR T cells per kg to determine the recommended Phase II dose. Dual antigen targeting is expected to reduce CD19 negative relapse which is a major limitation of single target CAR T therapy. The study will establish the safety profile of XenCART and support its further development in India.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

18

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Tamil Nadu
      • Vellore, Tamil Nadu, Indien, 632012
        • Rekrytering
        • Department of Haematology A Block 5th Floor Ranipet Campus Kilminnal Village Christian Medical College Vellore Ranipet Campus
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Dr Vikram Mathews, MBBS MD DM

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Subjects must meet ONE of the following

  1. Adults aged 18 to 65 years with relapsed or refractory CD19 and or CD20 positive B cell malignancy B ALL or B NHL
  2. B ALL At least 1 prior line of systemic therapy Ph positive ALL eligible after at least 1 BCR ABL1 TKI failure Morphological relapse with at least 5 percent blasts or MRD positive at least 10 to the power minus 4 by MFC eligible
  3. B NHL At least 2 prior lines including an anthracycline and an anti CD20 mAb At least 1 line if auto SCT ineligible or failed Transformed histologies require biopsy confirmation and prior therapy for the transformed component Refractory disease is defined as no response stable disease or progressive disease during or at the end of frontline immunochemotherapy such as R CHOP or similar OR early relapse within 3 to 12 months of end of treatment
  4. CD19 and or CD20 expression confirmed by IHC or flow cytometry on the most recent specimen within 6 months or at last relapse
  5. ECOG performance status 2 or less
  6. Adequate organ function bilirubin 1.5 times ULN or less AST ALT 3 times ULN or less creatinine 1.5 mg per dL or less or CrCl 50 mL per min or more ANC 1000 per microliter or more platelets 50000 per microliter or more LVEF 40 percent or more SpO2 92 percent or more on room air
  7. Adequate washout from prior therapy at least 2 weeks or 5 half lives whichever is shorter Anti CD20 mAb at least 4 weeks Checkpoint inhibitors at least 5 half lives
  8. Written informed consent with audio visual recording as per NDCT Rules 2019

Exclusion Criteria:

The presence of any of the following excludes enrollment

  1. Autologous SCT within 6 weeks of planned leukapheresis
  2. Prior allogeneic SCT any time
  3. Prior CAR T BiTE or other adoptive cell therapy unless CD19 or CD20 expression remains detectable on the most recent specimen
  4. Active CNS or meningeal disease prior CNS disease eligible if in remission 28 days with negative CSF
  5. Active second malignancy excluding adequately treated non melanoma skin cancer carcinoma in situ or any malignancy in CR 2 years
  6. Active HIV hepatitis B HBsAg positive hepatitis C HCV RNA detectable or tuberculosis infection
  7. Uncontrolled intercurrent illness NYHA III IV CHF LVEF less than 40 percent uncontrolled arrhythmia QTc greater than 480 ms active seizure disorder autoimmune disease on systemic immunosuppression uncontrolled hypertension or diabetes or active psychiatric illness precluding compliance
  8. Pregnancy or breastfeeding women of childbearing potential require negative beta hCG within 72 hours of leukapheresis and Day 0 infusion and effective contraception for 24 months post conditioning
  9. Active myelodysplastic syndrome therapy related MDS or therapy related AML
  10. Severe hypersensitivity to XenCAR T components lymphodepletion agents or to cilizumab not manageable with premedication

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 1.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 1 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Experimentell: Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 2.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 2 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Experimentell: Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 4.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 4 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of dose-limiting toxicities (DLT)
Tidsram: Day 0 (infusion) to Day +28

Number and percentage of participants experiencing at least one DLT, as defined in the protocol, at each dose level (unit: number of participants, %).

Day 0 (infusion) to Day +28
Incidence and maximum grade of cytokine release syndrome (CRS)
Tidsram: Day 0 to Day +28

Number and percentage of participants with CRS, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and maximum grade of ICANS
Tidsram: Day 0 to Day +28

Number and percentage of participants with immune effector cell-associated neurotoxicity syndrome, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Tidsram: Day 0 to Month 24

Number of participants with TEAEs/SAEs, graded by CTCAE (version as per protocol) (unit: number of participants).

Day 0 to Month 24
Maximum tolerated dose (MTD) / recommended Phase 2 dose (RP2D)
Tidsram: Day 0 to Day +28 of the last evaluable participant in each cohort

Highest XenCART dose level at which the DLT rate is acceptable per the dose-escalation rules, confirmed by DSMB (unit: CAR-T cells/kg).

Day 0 to Day +28 of the last evaluable participant in each cohort

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall response rate (ORR) in B-cell NHL
Tidsram: Day +28 and Day +90

Percentage of participants with complete or partial response per Lugano 2014 (PET-CT) (unit: %).

Day +28 and Day +90
Complete remission rate in B-ALL
Tidsram: Day +28 (±2)

Percentage of participants with CR/CRi by bone marrow morphology (unit: %).

Day +28 (±2)
MRD-negativity rate in B-ALL
Tidsram: Day +28 (±2)

Percentage of participants with MRD below 0.01% by multiparametric flow cytometry (unit: %).

Day +28 (±2)
Duration of response (DoR)
Tidsram: Up to Month 24

Time from first documented response to relapse, progression or death (unit: months).

Up to Month 24
Progression-free survival (PFS)
Tidsram: Up to Month 24

Time from infusion to progression, relapse or death from any cause (unit: months).

Up to Month 24

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Dr Vikram Mathews, Christian Medical College, Vellore, India

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 oktober 2026

Primärt slutförande (Beräknad)

14 september 2028

Avslutad studie (Beräknad)

14 september 2028

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

17 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data (IPD) will not be shared publicly because the study involves a limited number of participants, and sharing individual-level data may pose risks to participant privacy and confidentiality. De-identified data may be considered for sharing upon reasonable request, subject to applicable ethical, regulatory, and data protection requirements.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera